Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis

doi:10.4254/wjh.v17.i6.104073

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

HTML

Figures (1-5)

Sum=2

Jun 27, 2025 (publication date) through Jun 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Jun 27, 2025; 17(6): 104073
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.104073

Full Size Figure Download Figure

Figure 2 Analysis of biochemical parameters in serum in the treatment and control groups. A: Nanoparticles encapsulating rapamycin treatment decreased alkaline phosphatase in the primary biliary cholangitis (PBC) mouse models (^aP < 0.05); B: Comparison of alanine aminotransferase in the treatment and control group PBC mouse models. ALP: Alkaline phosphatase; ALT: Alanine aminotransferase.

Citation: Yang YS, Li XR, Wang ZM, Zheng L, Li JL, Cui XL, Song YB, Ma JJ, Guo HF, Gao LX, Zhou XH. Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis. World J Hepatol 2025; 17(6): 104073
URL: https://www.wjgnet.com/1948-5182/full/v17/i6/104073.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i6.104073